Skip to content

Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

Martin B. Leon, Craig R. Smith, Michael J. Mack, David Craig Miller, Jeffrey W. Moses, Lars Georg Svensson, Emin Murat Tuzcu, John G. Webb, Gregory P. Fontana, Raj Makkar, David L. Brown, Peter C. Block, Robert A. Guyton, Augusto Descalzi Pichard, Joseph E. Bavaria, Howard C. Herrmann, Pamela S. Douglas, John L. Petersen, Jodi J. Akin, William N. Anderson, Duolao Wang, Stuart Pocock

New England Journal of Medicine · 2010 · 7,285 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Leon, M. B., Smith, C. R., Mack, M. J., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R., Brown, D. L., Block, P. C., Guyton, R. A., Pichard, A. D., Bavaria, J. E., Herrmann, H. C., Douglas, P. S., Petersen, J. L., Akin, J. J., … Pocock, S. (2010). Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal of Medicine, 363(17), 1597–1607. https://doi.org/10.1056/nejmoa1008232

In text: (Leon et al., 2010)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve implantation (TAVI) has been suggested as a less invasive treatment for high-risk patients with aortic stenosis. METHODS: We randomly assigned patients with severe aortic stenosis, whom surgeons considered not to be suitable candidates for surgery, to standard therapy (including balloon aortic valvuloplasty) or transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve. The primary end point was the rate of death from any cause. RESULTS: A total of 358 patients with aortic stenosis who were not considered to be suitable candidates for surgery underwent randomization at 21 centers (17 in the United States). At 1 year, the rate of death from any cause (Kaplan–Meier analysis) was 30.7% with TAVI, as compared with 50.7% with standard therapy (hazard ratio with TAVI, 0.55; 95% confidence interval [CI], 0.40 to 0.74; P<0.001). The rate of the composite end point of death from any cause or repeat hospitalization was 42.5% with TAVI as compared with 71.6% with standard therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; P<0.001). Among survivors at 1 year, the rate of cardiac symptoms (New York Heart Association class III or IV) was lower among patients who had undergone TAVI than among those who had received standard therapy (25.2% vs. 58.0%, P<0.001). At 30 days, TAVI, as compared with standard therapy, was associated with a higher incidence of major strokes (5.0% vs. 1.1%, P=0.06) and major vascular complications (16.2% vs. 1.1%, P<0.001). In the year after TAVI, there was no deterioration in the functioning of the bioprosthetic valve, as assessed by evidence of stenosis or regurgitation on an echocardiogram. CONCLUSIONS: In patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI, as compared with standard therapy, significantly reduced the rates of death from any cause, the composite end point of death from any cause or repeat hospitalization, and cardiac symptoms, despite the higher incidence of major strokes and major vascular events. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).

  1. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging2015
  2. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients2011
  3. 2017 ESC/EACTS Guidelines for the management of valvular heart disease2017
  4. 2021 ESC/EACTS Guidelines for the management of valvular heart disease2021
  5. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients2016

Metadata from OpenAlex (CC0). Citations are generated from the published record.